Applied Dna Scie Stock Price, News & Analysis

Applied DNA Sciences (NASDAQ:APDN) announced that Dr. James A. Hayward is retiring as Chairperson and CEO effective June 18, 2025, after 20 years of service. The Board has appointed Judy Murrah as the new Chairperson and CEO, while retaining her position as President. Murrah brings over a decade of operational leadership at Applied DNA and extensive experience from Symbol Technologies, where she helped grow the company to $2B in revenue. She also held strategic leadership roles at Motorola and is an inventor on 14 U.S. patents with an MBA from Harvard Business School. The company's executive team includes Clay Shorrock as Chief Legal Officer and President of LineaRx, and Beth Jantzen as CFO. Under Murrah's leadership, the company aims to focus on its biotherapeutic manufacturing capabilities and drive increased operating efficiency.

Applied DNA Sciences (NASDAQ:APDN), a PCR-based DNA technologies company, announced it will resume its regular quarterly investor call schedule. The company will begin this practice with its fiscal third quarter 2025 financial results release, scheduled for mid-August 2025. As part of this transition, Applied DNA has cancelled its previously planned intra-quarter investor call that was set for June 17, 2025.

Applied DNA Sciences (NASDAQ:APDN) has announced the rescheduling of its intra-quarter webcast and investor update call from June 3 to June 17, 2025. The postponement is due to the implementation of a reverse stock split that will take effect on June 2, 2025. The webcast will begin at 4:30 p.m. Eastern Time and will include prepared remarks from the management team, followed by a Q&A session with sell-side analysts and institutional investors. The event will be accessible via phone and webcast, with replay options available for 7 days after the call. An accompanying slide presentation will be available during the webcast and on the company's investor relations website.

["-"]

Applied DNA Sciences (NASDAQ:APDN) announced a 1-for-15 reverse stock split effective June 2, 2025. The company's outstanding shares will be reduced from approximately 7.8 million to 519 thousand. Trading will continue under the symbol "APDN" with a new CUSIP number (03815U607). The reverse split aims to meet Nasdaq's $1.00 minimum bid price requirement for continued listing. The split was approved by stockholders on May 22, 2025, granting the Board discretion for a ratio between 1:5 and 1:50. Proportional adjustments will be made to stock options, restricted stock units, and warrants. No fractional shares will be issued, and the $0.001 par value remains unchanged.

Applied DNA Sciences (NASDAQ:APDN) reported Q2 FY2025 financial results with total revenues of $983K, up 6% year-over-year. The company's LineaRx segment, focused on therapeutic DNA production, saw a 44% revenue increase, while MDx Testing Services revenue declined 33%. The company reported a net loss of $3.3M, improved from $4.5M loss in Q2 FY2024, and held cash and equivalents of $6.8M. Following strategic restructuring, Applied DNA expects quarterly cash burn to decrease starting Q3 FY2025. The company's GMP Site 1 facility, operational since January, can support annual revenue of $10-30M. Notable developments include new customer acquisitions, follow-on orders, and planned launch of LineaPCR™ in Q4'25. The company positions LineaRx as North America's largest PCR-based producer of cell-free DNA, focusing on meeting biopharma's enzymatic DNA demand.

Applied DNA Sciences (NASDAQ:APDN) has announced it will release its Q2 FY2025 financial results on May 15, 2025, after U.S. market close. The company will file its Form 10-Q concurrently. Following its Annual Meeting of Stockholders on May 22, Applied DNA will host an intra-quarter investor update call on June 3, 2025, at 4:30 p.m. ET, where management will discuss strategic priorities.

The conference call will be accessible via multiple channels, including domestic (844-887-9402), international (412-317-6798), and Canadian (866-605-3852) dial-in numbers. A webcast replay will be available for 7 days following the call, with access codes provided for different regions.

Applied DNA Sciences' (NASDAQ:APDN) subsidiary LineaRx has completed its transition to a U.S.-based supply chain for critical input materials used in its LineaDNA™ and LineaIVT™ platforms. This strategic move, responding to the 2024 BIOSECURE Act and customer demand, positions the company to support the reshoring of biopharmaceutical manufacturing operations in the United States.

As the largest PCR-based cell-free DNA producer in the U.S., LineaRx now sources over 75% of its manufacturing cost components domestically, including DNA template materials and manufacturing enzymes. The company's proprietary PCR-based platform enables rapid production of high-fidelity, cell-free DNA in quantities from milligram to multi-gram scale for genetic medicines development.

Applied DNA Sciences (NASDAQ:APDN) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, which specializes in PCR-based DNA technologies, received confirmation from Nasdaq's Listing Qualifications Department on April 7, 2025.

The company had previously fallen out of compliance on November 12, 2024, when it failed to maintain the required minimum bid price of $1.00 over 30 consecutive business days. To rectify this situation, APDN needed to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.

The company exceeded this requirement by maintaining the minimum bid price for 16 consecutive business days, from March 14 through April 4, 2025. With this achievement, Nasdaq has confirmed the matter is now closed.

Applied DNA Sciences (NASDAQ:APDN) is repositioning its TR8™ PGx pharmacogenomics testing service to focus on specific use cases, starting with pre-emptive testing for DPYD gene variants. This initiative follows an FDA safety announcement regarding patients with DPYD genetic variants who may experience severe toxicities when taking fluoropyrimidine-based cancer drugs.

The company's TR8 PGx test, approved by the New York State Department of Health, can identify individuals with DPYD genotypes affecting DPD enzyme activity, important for metabolizing drugs like capecitabine and fluorouracil (5-FU). These medications, with approximately 924,000 prescriptions in 2022, are commonly used in treating various cancers including colorectal, breast, and cervical.

Statistics show that about 1 in 1,000 patients carry two DPYD gene variants causing DPD enzyme absence, while 3-8% of the population has one variant resulting in lower enzyme levels, with higher frequency in African Americans.